Do HIV disease progression and HAART response vary among injecting drug users in Europe?

European Journal of Epidemiology

Volumn 20, Issue 9, 2005, Pages 795-804

  Van Asten, Liselotte ^a,j   Zangerle, Robert ^b   Aguado, Ildefonso Hernández ^c   Boufassa, Faroudy ^d   Broers, Barbara ^e   Brettle, Raymond P ^f   Robertson, J Roy ^g   McMenamin, Jim ^h   Coutinho, Roel A ^a,i   Prins, Maria ^a  

^a MUNICIPAL HEALTH SERVICE   (Netherlands)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^d BICÊTRE HOSPITAL   (France)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f WESTERN GENERAL HOSPITAL   (United Kingdom)

^g Edinburgh Drug Addiction Study   (United Kingdom)

^h Scottish Centre for Infection and Environmental Health   (United Kingdom)

ⁱ UNIVERSITY OF AMSTERDAM   (Netherlands)

^j NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

more..

Author keywords

Europe; Highly Active Antiretroviral Therapy; HIV disease progression; Injecting drug users

Indexed keywords

CD4 ANTIGEN;

ACCIDENT; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; DE LANGE SYNDROME; DEATH; DISEASE COURSE; DRUG USE; EUROPE; FEMALE; FRANCE; GEOGRAPHY; GLASGOW COMA SCALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMICIDE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; RISK ASSESSMENT; RISK FACTOR; SEROCONVERSION; SPAIN; SUICIDE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; EUROPE; FEMALE; HIV INFECTIONS; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; SURVIVAL ANALYSIS;

EID: 25444441187     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-005-1049-0     Document Type: Article

References (48)

1. K Porter A Babiker K Bhaskaran J Darbyshire P Pezzotti AS Walker 2003 Determinants of survival following HIV-1 seroconversion after the introduction of HAART Lancet 362 1267 1274
2. LC van Asten F Boufassa V Schiffer 2003 Limited effect of highly active antiretroviral therapy among HIV-positive injecting drug users on the population level Eur J Public Health 13 347 349
3. S Perez-Hoyos J Del Amo R Muga 2003 Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: Differences by transmission category AIDS 17 353 359
4. KE Poundstone RE Chaisson RD Moore 2001 Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy AIDS 15 1115 1123
5. P Pezzotti M Dorrucci A Donisi 2003 [Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART). [Italian] Epidemiologia e Prevenzione 27 348 355
6. M Dorrucci M Balducci P Pezzotti A Sinicco F Alberici G Rezza 1999 Temporal changes in the rate of progression to death among Italians with known date of HIV seroconversion: estimates of the population effect of treatment. Italian HIV Seroconversion Study (ISS) J Acquir Immune Def Syndr 22 65 70
7. M Egger M May G Chene 2002 Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies Lancet 360 119 129
8. A Mocroft S Madge AM Johnson 1999 A comparison of exposure groups in the EuroSIDA Study: Starting highly active antiretroviral therapy (HAART), response to HAART, and survival J Acquir Immune Def Syndr Hum Retrovirol 22 369 378
9. DD Celentano N Galai AK Sethi 2001 Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users AIDS 15 1707 1715
10. Press N, Tyndall MW, Wood E, Hogg RS, Montaner JS. Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. J Acquir Immune Def Syndr JID - 100892005 2002; 31(Suppl 3): S112-S117.
11. GM Lucas LW Cheever RE Chaisson RD Moore 2001 Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection J Acquir Immune Def Syndr 27 251 259
12. JH Arnsten PA Demas RW Grant 2002 Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users J Gen Intern Med 17 377 381
13. GM Lucas KA Gebo RE Chaisson RD Moore 2002 Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic AIDS 16 767 774
14. A Palepu B Yip C Miller 2001 Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use AIDS JID - 8710219 15 423 424
15. A Babiker J Darbyshire P Pezzotti 2003 Short-term CD4 cell response after highly active antiretroviral therapy initiated at different times from seroconversion in 1,500 seroconverters J Acquir Immune Def Syndr JID - 100892005 32 303 310
16. F Dronda S Moreno A Moreno JL Casado MJ Perez-Elias A. Antela 2002 Long-term outcomes among antiretroviral-naive human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression Clin Infect Dis JID - 9203213 35 1005 1009
17. A Palepu M Tyndall B Yip MV O'Shaughnessy RS Hogg JS Montaner 2003 Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use J Acquir Immune Def Syndr JID - 100892005 32 522 526
18. UB Dragsted A Mocroft S Vella 2004 Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: A EuroSIDA study J Infect Dis JID - 0413675 190 148 155
19. M Prins RP Brettle JR Robertson 1999 Geographical variation in disease progression in HIV-1 seroconverted injecting drug users in Europe? Int J Epidemiol 28 541 549
20. M Prins AI Hernandez RP Brettle 1997 Pre-AIDS mortality from natural causes associated with HIV disease progression: Evidence from the European Seroconverter Study among injecting drug users AIDS 11 1747 1756
21. RB Geskus 2001 Methods for estimating the AIDS incubation time distribution when date of seroconversion is censored Stat Med 20 795 812
22. M Prins CA Sabin CA Lee H Devereux RA Coutinho 2000 Pre-AIDS mortality and its association with HIV disease progression in haemophilic men, injecting drug users and homosexual men AIDS 14 1829 1837
23. SR Seaman RP Brettle SM Gore 1997 Pre-AIDS mortality in the Edinburgh City Hospital HIV cohort Stat Med 16 2459 2474
24. SAS Institute I. SAS/STAT Software: Changes Enhancements through Release 6.12. SAS Institute, 1996.
25. PJ Diggle K Liang SL Zeger 1995 Analysis of Longitudinal Data Clarendon Press Oxford
26. N Carré M Prins L Meyer 1997 Has the rate of progression to AIDS changed in recent years? AIDS 11 1611 1618
27. J Del Amo J del Romero A Barrasa 2002 Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999 Sex Transmit Infect 78 255 260
28. P Pehrson S Lindback C Lidman H Gaines J Giesecke 1997 Longer survival after HIV infection for injecting drug users than for homosexual men: Implications for immunology [see comments] AIDS 11 1007 1012
29. HJ van Haastrecht AJ van den Hoek RA Coutinho 1994 High mortality among HIV-infected injecting drug users without AIDS diagnosis: Implications for HIV infection epidemic modellers? AIDS JID - 8710219 8 363 366
30. M Prins PJ Veugelers 1997 Comparison of progression and non-progression in injecting drug users and homosexual men with documented dates of HIV-1 seroconversion. European Seroconverter Study and the Tricontinental Seroconverter Study AIDS 11 621 631
31. L Copeland J Budd JR Robertson RA Elton 2004 Changing patterns in causes of death in a cohort of injecting drug users, 1980-2001 Arch Intern Med JID - 0372440 164 1214 1220
32. JK Rockstroh U Spengler 2004 HIV and hepatitis C virus co-infection Lancet Infect Dis JID - 101130150 4 437 444
33. S Horster FD Goebel 2004 HAART-prolonged life of HIV-infected patients should not be shortened by hepatitis C Infection JID - 0365307 32 369 371
34. C Lewden D Salmon P Morlat 2005 Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS Int J Epidemiol JID - 7802871 34 121 130
35. L van Asten I Verhaest S Lamzira 2004 Spread of hepatitis C virus among European injection drug users infected with HIV: A phylogenetic analysis J Infect Dis 189 292 302
36. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology 2002; 36(5 Suppl 1).
37. European Centre for the Epidemiological Monitoring of AIDS. HIV/AIDS Surveillance in Europe. First Quarterly Report 1997. 1997.
38. Anonymous 2000 Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: A collaborative re-analysis. Collaborative group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted action. Concerted action on seroconversion to AIDS and death in Europe Lancet 355 1131 1137
39. TE Yamashita JP Phair A Munoz 2001 Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study AIDS 15 735 746
40. PW Hunt SG Deeks B Rodriguez H Valdez SB Shade DI Abrams 2003 Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy AIDS 17 1907 1915
41. E Nicastri A Chiesi C Angeletti 2005 Clinical outcome after 4 years follow-up of HIV-seropositive subjects J Med Virol 76 153 160
42. M Frischer D Goldberg M Rahman L Berney 1997 Mortality and survival among a cohort of drug injectors in Glasgow, 1982-1994 Addiction 92 419 427
43. F Dronda J Zamora S Moreno 2004 CD4 cell recovery during successful antiretroviral therapy in naive HIV-infected patients: The role of intravenous drug use AIDS 18 2210 2212
44. CJ Smith CA Sabin FC Lampe 2003 The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy AIDS 17 963 969
45. M Zaccarelli A Barracchini P De Longis 2002 Factors related to virologic failure among HIV-positive injecting drug users treated with combination antiretroviral therapy including two nucleoside reverse transcriptase inhibitors and nevirapine Aids Patient Care STDS 16 67 73
46. O Kirk A Mocroft C Pradier 2001 Clinical outcome among HIV-infected patients starting saquinavir hard AIDS 15 999 1008
47. A Krol C Flynn D Vlahov F Miedema RA Coutinho EJC van Ameijden 1999 New evidence to reconcile in vitro and epidemiologic data on the possible role of heroin on CD4+ decline among HIV-infected injecting drug users Drug Alcohol Depend 54 145 154
48. M Prins JR Robertson RP Brettle 1999 Do gender differences in CD4 cell counts matter? AIDS 13 2361 2364